EXOZYMES INC. EXOZ

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

are ubiquitous in modern life - they form the basis of medicines, fuels, plastics, food, and colors, among many other applications that

together contribute to our ability to live "the good life" in the modern world.

chemicals from nature via traditional extraction methods is often inefficient and often requires large amounts of biological material

to extract the necessary amounts of the desired chemical compounds. So, despite maybe being sustainable, it is not enough to supply the

Last close 4.00 2026-10-23
Market cap $37.1M 2026-06-30 share count
52-week range 3.71 - 18.40

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.09

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022
Revenue ——$70.1K—
R&D $3.7M$1.9M$527.5K—
SG&A $6.0M$4.1M$1.3M—
Operating income -$9.7M-$5.9M-$1.8M—
Pre-tax income -$9.3M-$5.9M-$2.0M—
Income tax $105.2K—$42.3K—
Net income -$9.2M-$5.9M-$2.0M—
EPS, basic -1.09-0.89-0.33—
EPS, diluted -1.09-0.89-0.33—
Shares, diluted (wtd. avg.) 8.4M6.6M6.3M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022
Cash and equivalents $3.0M$9.7M$66.5K$558.6K
Total current assets $3.9M$10.8M$1.2M—
Property, plant and equipment $764.4K$882.4K$753.4K—
Total assets $6.0M$13.0M$3.6M—
Accounts payable $1.2M$924.3K$702.9K—
Total current liabilities $1.6M$1.3M$2.4M—
Total liabilities $2.6M$2.6M$3.9M—
Retained earnings -$21.1M-$11.9M-$6.1M—
Total equity $3.4M$10.4M-$384.3K$1.4M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022
Operating cash flow -$6.5M-$8.5M-$1.2M—
Depreciation and amortisation $288.0K$267.4K$196.9K—
Stock-based compensation $2.0M$1.1M$281.5K—
Capital expenditure $169.9K$396.5K$288.7K—
Investing cash flow -$150.2K-$359.2K-$311.2K—
Financing cash flow -$27.7K$18.5M$1.0M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013563.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -10M -7.5M -5M -2.5M 0 2.5M Revenue, FY2023: 70.1K Net income, FY2023: -2M Net income, FY2024: -5.9M Net income, FY2025: -9.2M FY2022 FY2023 FY2024 FY2025
Fiscal year FY2022FY2023FY2024FY2025
Revenue — $70.1K — —
Gross profit — — — —
Net income — -$2.0M -$5.9M -$9.2M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Material agreement signed Item 1.01
  • Regulation FD disclosure Item 7.01
  • Material agreement signed Item 1.01
  • Regulation FD disclosure Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Other event Item 8.01
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%